Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
64.3 USD | +0.47% | +6.34% | +2.85% |
07-16 | JPMorgan Adjusts Price Target on Incyte to $59 From $60, Maintains Neutral Rating | MT |
07-16 | Goldman Sachs Adjusts Price Target on Incyte to $61 From $60, Maintains Neutral Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.85% | 14.39B | |
+7.46% | 100B | |
+8.42% | 42.34B | |
-11.86% | 32.76B | |
+79.72% | 29.46B | |
-11.71% | 16.31B | |
-6.77% | 12.23B | |
+177.16% | 10.47B | |
+1.57% | 8.97B | |
-56.13% | 8.84B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Transcript : Incyte Corporation Presents at 38th Annual J.P Morgan Healthcare Conference, Jan-13-2020 through Jan-16-2020